Journey Medical Corporation to Present Phase 3 Data on Emrosi™ for Rosacea at 2025 SDPA Summer Conference

Journey Medical (DERM) announced Phase 3 trial data for Emrosi, an FDA-approved rosacea treatment, will be presented at the SDPA 2025 conference, highlighting its body weight-independent efficacy. The analysis of two trials showed Emrosi's superiority over placebo and doxycycline in treating moderate-to-severe rosacea, with a good safety profile, potentially establishing it as a new standard of care. Despite these positive results, concerns remain regarding the company's financial stability and its dependence on Emrosi's commercial success.

Analysis

Journey Medical Corporation (DERM) is poised to present compelling Phase 3 clinical trial data for Emrosi™, its FDA-approved (November 2024) treatment for moderate-to-severe papulopustular rosacea, at the SDPA 2025 conference. The analysis from two trials, MVOR-1 and MVOR-2, highlights Emrosi's body weight-independent efficacy, a significant advantage simplifying prescribing, and demonstrated superior results in Investigator’s Global Assessment (IGA) treatment success and reduction in total inflammatory lesion counts compared to both placebo and doxycycline. For example, in the MVOR-1 trial, IGA treatment success for Emrosi was 75.5% (≤ median body weight) and 56.3% (> median body weight), substantially outperforming placebo (28.2% and 35.3% respectively). This positions Emrosi, targeting a market of over 16 million Americans, as a potential new standard of care. However, these positive clinical developments are substantially counterbalanced by a significant disclosure of "substantial doubt about the company's ability to continue as a going concern," raising serious concerns about its financial viability and capacity to effectively commercialize Emrosi. The company's heavy dependence on Emrosi's market success is a key risk. Furthermore, insider sentiment appears negative, with 10 sales and zero purchases by insiders in the past six months, including disposition of 165,117 shares by the President & CEO. While institutional ownership saw 22 new additions versus 19 decreases in the last quarter and one analyst issued a "Buy" rating in May 2025, the overall financial instability and insider selling cast a significant shadow over Emrosi's promising clinical profile.

Key Decisions for Investors

• Investors should critically evaluate the significant 'going concern' risk highlighted by Journey Medical, as this financial instability could severely hamper the commercialization and market penetration of the clinically promising Emrosi™.
• The consistent pattern of insider selling, with 10 sales and no purchases in the last six months including significant sales by the CEO, warrants considerable caution and may reflect internal concerns despite positive product developments.
• Potential or current investors should closely monitor the company's forthcoming financial statements, cash burn rate, any capital raising efforts, and early sales figures for Emrosi™ to gauge the viability of its commercial strategy and its ability to resolve the going concern status.